Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
Sponsor: Kite, A Gilead Company
Terminated
The study was terminated due to the sponsor's decision to discontinue the clinical trial.
Other terminated trials from Kite, A Gilead Company
Other Solid Tumor trials with similar outcome
Listed as NCT03139370, this PHASE1 trial focuses on Solid Tumor and remains terminated or withdrawn. Sponsored by Kite, A Gilead Company, it has been updated 44 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
44 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jul 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 39 earlier versions
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
-
Nov 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
-
May 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
-
Mar 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
-
Oct 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE1
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE1
-
Jun 2020 — Aug 2020 [monthly]
Recruiting PHASE1
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE1
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE1
-
Aug 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE1
-
Apr 2019 — Jul 2019 [monthly]
Recruiting PHASE1
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE1
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE1
-
Oct 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Feb 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kite, A Gilead Company
For direct contact, visit the study record on ClinicalTrials.gov .